chrisvoncsefalvay/vaers-outcomes huggingface dataset:
General pain; Headache; This spontaneous case was reported by a patient family member or friend and describes the occurrence of PAIN (General pain) and HEADACHE (Headache) in a female patient of an unknown age who received mRNA-1273 (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Intramuscular) at an unspecified dose. On an unknown date, the patient experienced PAIN (General pain) and HEADACHE (Headache). At the time of the report, PAIN (General pain) and HEADACHE (Headache) had not resolved.        The action taken with mRNA-1273 (Intramuscular) was unknown.       No concomitant medications provided. No treatment information provided.
I had hearing loss, primarily in my right ear, off and one for about 2 weeks. It felt like I had my head in a space helmet.
Received DTap/IPV/MMR-Varivax (ProQuad) within 5 minutes child back with swelling both lower eyelids and 1 hive below Left eye. Mild lower lip swelling not short breath wheezing-CTA 100% given Benadryl 12.5mg per tube with 10 ml. Water flush. Re-evaluated two more time over next 30 min with stable. Lung fine and resolving swelling/hives. No respiratory distress. Zyrtec every 10hours for 3days. no further swelling or wheezing.
BEDRIDDEN; SORE ALL OVER; WEAK MUSCLES; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 043A21A, expiry: 21-JUN-2021) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported.  On APR-2021, the subject experienced bedridden. On APR-2021, the subject experienced sore all over. On APR-2021, the subject experienced weak muscles. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from bedridden on APR-2021, and the outcome of sore all over and weak muscles was not reported. This report was non-serious.
At 0902 am, pt received Afluria in his left deltoid and typhoid in his right. Very shortly after that the patient c/o "not feeling well". Pt lost consciousness for no more than 30seconds and came back very confused and disoriented. At 0904, rapid response was called. Pt was placed in Trendelenburg position and was assessed to be very pale and diaphoretic. BP dropped to 78/88 HR 45. Around 0905, pt was more oriented but stated that he still felt very light headed. Patient had not eaten food prior to the event. He denies any sickness or any issues with vaccines prior to this event. Pt drank a Gatorade and ate a nutrigrain bar. Repeat vitals at 108/54. Continued to monitor pt as he became more engaged and aroused. He slowly adjusted to standing without feelings of syncope and was discharge by medical doctor on call in stable condition.
Starting 48 hours after receiving the vaccine, I developed a rash on my inner arms that extended from wrist to armpit, inner thighs from knee to groin, trunk from waist to below breast area that wrapped around the sides to my back. Also, the rash extended slightly onto my chest from my armpit area but not directly to midline. It was a very red rash and looked like a bad sunburn. The rash lasted about 5-6 days after receiving the vaccine, and at that time itching started and resolved within a few days afterwards. On 12/24/2021, I saw an allergist, who, after looking at my pictures and listening to my history, he said I had Type 4 hypersensitivity reaction most likely to the spike protein. He said my T cells were "angry" and this was a very robust immune response. The doctor specifically ruled out Type 1, 2 and 3 reactions in his report, which I have in my possession. Also, he gave me a lab work request to hold onto so when the 2nd booster was approved and I received it, I could have this done at the 48 hour mark when likely the reaction I had previously may present itself.
Injection site redness; injection site swelling; myalgia; joint stiffness; fatigue; sore shoulder; soreness of joints; Condition aggravated; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included kidney abscess. Concurrent medical conditions included fibromyalgia, psoriatic arthritis, fatigue (worsened after receiving the 1st dose of Shingrix) and stiff joint (worsened after receiving the 1st dose of Shingrix).   On 22nd April 2019, the patient received the 1st dose of Shingrix (intramuscular). On 22nd April 2019, less than a day after receiving Shingrix, the patient experienced injection site erythema, injection site swelling, myalgia, stiff joint, fatigue, shoulder pain, joint pain and condition aggravated. On 23rd April 2019, the outcome of the injection site swelling was recovered/resolved. On an unknown date, the outcome of the injection site erythema, myalgia, stiff joint, fatigue and shoulder pain were not recovered/not resolved and the outcome of the joint pain was recovered/resolved and the outcome of the condition aggravated was unknown.   It was unknown if the reporter considered the injection site erythema, injection site swelling, myalgia, stiff joint, fatigue, shoulder pain, joint pain and condition aggravated to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix on right deltoid. On the day of vaccination, the patient experienced redness, swelling at the injection site.  The patient also experienced soreness of joints and shoulder, joint stiffness, myalgia that  The reporter consented to follow up. This case has been linked with case US2019073215 reported by the same reporter.
I awoke in the middle of the night feeling extremely cold, as if I had the "chills".  I took two Ibuprofen and after 20 minutes, I was able to sleep again until 7:00AM.
In 7/00, the pt received her 1st Lymerix injection and within 30 minutes, post vax, the pt experienced nausea, dizziness, headache, fatigue and localized injection site reaction. The pt was not treated for the events. As of 8/23/00, the events reportedly resolved without sequelae, within 10 hours.
pt recv vax & w/in hr of vax pt hypotensive, dizziness, nausea, profuse vomiting, migraine;pt unable to stand sometimes for day;
Patient fainted and had low blood pressure/heart rate (45) about 5 minutes after receiving flu and covid booster vaccine. Blood pressure readings are as follows, 1100am after incident 101/58, 47 heart rate; 103/58, 51 heart rate; 103/67, 52 heart rate. Patient was given full glass of water and a small fruit bar. The patient raise his legs while waiting in lobby area. Rechecked blood pressure at 11:15am where it was 115/81, heart rate 57. Patient declined for us to call 911. Urged him to go home, have a meal, take it easy, and keep an eye on heart rate. Patient denies previous infection, reaction to vaccines, or history of seizures. wife will stay with him rest of day. Informed him to avoid driving and alcohol today as well. The patient left at 11:23. The patient called his doctor and he was not concerned. The patient has an appointment with doctor in a few months.
Upon inserting the syringe, what is believed to be the majority of the vaccine in the barrel ejected out of the side of the lure lock section of the needle base. recognized the feeling of fluid dripping down his arm. He repeatedly told me that he didn't feel any medication enter his arm. A considerable amount of the dose spilt to the floor. Through this determination, we assessed that more than half of the dose , if not all, dripped out of the syringe prematurely. We called CDC for guidance, and according to there advice, we vaccinated the patient in his right deltoid, as opposed to his left where the spillage occurred.
shortness of breath, chest pain causing patient to awaken from sleep, fatigue, dizziness, joint pain and swelling
Beginning twelve hours (8pm) after the 2nd dose I got a severe headache with a high fever of 102 degrees. I took two 325mg tablets of Tylenol around 9:30pm and went to bed. I couldn't sleep until around 1am when I vomited about 7 times in a row. When I woke up the next day, I still had a lower grade fever that fluctuated and felt sore all over with a headache. I barely had any appetite and all I ate all day was some crackers with peanut butter and a lot of apple juice and water. I took one additional 325mg Tylenol. I slept for about four hours in the middle of the day being exhausted. I took two additional 325mg Tylenol before going to bed at 9:30pm. As of this morning, two days after the shot, I am feeling mostly back to normal. Slight headache and a bit sore but I have an appetite back and am still relaxing.
This spontaneous report was received from a physician via company representative refers to a 15 year old female patient. There was not pertinent medical history. On an unknown date the patient was vaccinated with the second dose of GARDASIL injection, 1 single shot, (lot number, expiration date, route and dosage were not reported). Concomitant therapy was not reported. The physician informed that on an unknown date within a month of receiving the second dose of GARDASIL the patient began experiencing severe shoulder pain. No adverse effects were reported with the first dose. The patient needed physical therapy as treatment for the adverse event, a magnetic resonance imaging (MRI) was performed as diagnostic study. The patient sought an unspecified medical attention for the adverse event. The reporter determined that the shoulder pain was significant disability or incapacity. Additional information has been requested.
This spontaneous report as received from a medical assistant refers to 2 patients of unknown age. On an unknown dates, the patients were vaccinated with improperly stored doses of PNEUMOVAX 23 lot # reported as N012890. No adverse effects were reported. Administered doses of vaccines experienced the temperature excursion of 31 degrees Fahrenheit or colder for 12 hours but number of cold cycles were unknown.
Aches, low level fever, fatigue, loss of appetite, starting approx. 12 hours after vaccination and sustained over the course of 3 days
Fever of 104° followed by trunk rash Was informed over the phone she had Roseola based on symptoms.
having pain where the bump or where the swollen lymph node is; had a "swollen lymph node under the arm" on the vaccination site; had a "swollen lymph node under the arm" on the vaccination site; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the parent.  A 15 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 10Sep2021 (Lot number: FF2587, Expiration Date: 31Dec2021) at the age of 15 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Verbatim: Kawasaki's disease" (ongoing), notes: Verbatim: Kawasaki's disease, Information for Other Conditions: diagnosed about 7 years ago. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Lot Number / Expiry Date: , Lot: FC3182, Exp: 21Oct2021, Route, Anatomical Location: Unknown by injection , No. of Previous Doses: 1), administration date: 20Aug2021, when the patient was 15 years old, for Covid-19 immunization. The following information was reported: VACCINATION SITE SWELLING (non-serious), LYMPHADENOPATHY (non-serious) all with onset 12Sep2021, outcome "not recovered" and all described as "had a "swollen lymph node under the arm" on the vaccination site"; PAIN (non-serious), outcome "unknown", described as "having pain where the bump or where the swollen lymph node is".  Follow-up attempts are completed. No further information is expected.
Joint pain and stiffness in both knees, shoulder, neck.  Tingling and numbness in legs, arms.  Anxiety  Gait problems/limited mobility Joints are cracking loud all the time
My granddaughter had the 3 shot series of GARDASIL approximately 2-3 yrs ago. She was a perfectly healthy normal teenager. Then you had the GARDASIL. Since then she continues to suffer from debilitating headaches and has seizures - she had been seen by a neurologist and there tests show no signs of Epilepsy, just some sort of "seizure disorder". This has made a drastic change in her lifestyle. She no longer goes out with her friends for fear of having a seizure, finds it impossible to hold a job because of these problems, and lives with constant anxiety over what will happen next. Also, she has a younger sister who had two of the shots and ever since has had problems with dizziness and blacking out. These were both perfectly healthy young girls before these shots.
No pain at injection time, raised bump and sore arm have now continued a week affecting sleep and some day to day movements
Date vials moved from freezer to refrigerator on 15-Jun-22 and administered on 19-Jul-22; doses given after the 30 day beyond use date; Dose 1 and Dose 2 received 36 days apart; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (doses given after the 30 day beyond use date), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and Dose 2 received 36 days apart) and PRODUCT STORAGE ERROR (Date vials moved from freezer to refrigerator on 15-Jun-22 and administered on 19-Jul-22) in a 22-year-old female patient who received mRNA-1273 (Spikevax) (batch nos. 060A22A and 05HA22A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 13-Jun-2022 at 12:12 PM, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On 19-Jul-2022, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to .5 milliliter. On 19-Jul-2022,  after starting mRNA-1273 (Spikevax), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and Dose 2 received 36 days apart). On 19-Jul-2022 at 12:40 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (doses given after the 30 day beyond use date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Date vials moved from freezer to refrigerator on 15-Jun-22 and administered on 19-Jul-22). At the time of the report, EXPIRED PRODUCT ADMINISTERED (doses given after the 30 day beyond use date), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and Dose 2 received 36 days apart) and PRODUCT STORAGE ERROR (Date vials moved from freezer to refrigerator on 15-Jun-22 and administered on 19-Jul-22) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided. Doses were given to an unknown amount of patients on 18-Jul-2022 and 19-Jul-2022. Date vials moved from freezer to refrigerator reported as 15-Jun-2022. No adverse events were reported by the patient. No treatment medication was provided.
pt recv vax & exp diarrhea which was treated w/Bactrim;w/in several wk pt was affected by arthritis & vasculitis, conforming to the criteria for serum sickness, in the judgement of any American rheumatologist;27MAR96 pt is recovering;
4 hrs after shot was given, pt had her thigh swollen and red at the location of the shot. She cried inconsolably for 1 hr. The shot location was also very warm to the touch. She was well by the time the Dr. saw her.
Systemic: Chest Tightness / Heaviness / Pain-Medium, Systemic: Exhaustion / Lethargy-Medium, Additional Details: mom reported child had decrease in white cell counts and chest pain
pt recv vax 26MAR98 & 7APR98 pt devel a total body rash, approx 2 days later pt exp bilat joint pain primarily in the wrist & ankles;
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. In January 2011, the patient was inoculated with ZOSTAVAX (lot number, dosage and route of administration not provided), as recommended for routine adult health maintenance for the prevention of shingles. The ZOSTAVAX did not prevent shingles as intended, and the patient subsequently contracted a persistent strain condition of herpes zoster. In July 2016, the patient was treated for a blistering vesicular outbreak, which was diagnosed as herpes zoster or shingles. The outcome of the events is unknown. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Patient reported that she had an allergic type reaction to the vaccine, visited the doctors office the next day and has fully recovered.
prev dose administration date 24Feb2021, prev dose dose number=1, prev dose administration date 25Feb2021, prev dose dose number=2,; Headache; chills; swollen lymph nodes under left arm/swolllen neck lymph nodes; fever blisters; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 25Feb2021 (Lot number: Unknown) at the age of 65 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Atrial runs and trigeminal neuralgia" (unspecified if ongoing); "Atrial runs and trigeminal neuralgia" (unspecified if ongoing). Concomitant medication(s) included: DILTIAZEM; GABAPENTIN; OXCARBAZEPINE; BUPROPION. Past drug history included: Augmentin, reaction(s): "Known Allergy: Augmentin", notes: known allergies:Augmentin; Clindamycin, reaction(s): "Known Allergy: clindamycin", notes: known allergies:clindamycin. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: Unknown. Not available/provided to reporter at the time of report completion, Location of injection: Arm Left), administration date: 24Feb2021, when the patient was 65 years old, for Covid-19 Immunization. The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 21Jan2022, outcome "unknown", described as "prev dose administration date 24Feb2021, prev dose dose number=1, prev dose administration date 25Feb2021, prev dose dose number=2,"; HEADACHE (non-serious) with onset 21Jan2022, outcome "not recovered", described as "Headache"; CHILLS (non-serious) with onset 21Jan2022, outcome "not recovered", described as "chills"; LYMPHADENOPATHY (non-serious) with onset 21Jan2022, outcome "not recovered", described as "swollen lymph nodes under left arm/swolllen neck lymph nodes"; ORAL HERPES (non-serious) with onset 21Jan2022, outcome "not recovered", described as "fever blisters". Therapeutic measures were not taken as a result of inappropriate schedule of product administration, headache, chills, lymphadenopathy, oral herpes.  Additional information: Vaccine Facility type was Pharmacy or Drug Store. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received Diltiazem, gabapentin, oxcarbazepine, and bupropion within 2 weeks of vaccination. Adverse event did not require a visit to Emergency Room/Physician Office. Prior to vaccination, the patient was not diagnosed with COVID-19; Since the vaccination, the patient has not been tested for COVID-19. Known allergies to Augmentin and clindamycin. Other medical history included Atrial runs and trigeminal neuralgia. The patient also received third dose of Pfizer BioNTech COVID-19 vaccine in arm left on 20Jan2022 at 01:15 PM as dose 3( booster) single for Covid-19 immunisation.  The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202200148526 similar report from same reporter
Pt brought to office by his mother 6/30/03 with a rash. He was diagnosed by MD with chicken pox. He had approximately 25 vesicles.
Aches and pains; Fever; Headache; Chills; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Aches and pains), PYREXIA (Fever), HEADACHE (Headache) and CHILLS (Chills) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 25-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Mar-2021, the patient experienced PAIN (Aches and pains), PYREXIA (Fever), HEADACHE (Headache) and CHILLS (Chills). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, PAIN (Aches and pains), PYREXIA (Fever), HEADACHE (Headache) and CHILLS (Chills) outcome was unknown.            Concomitant medications were not reported.
Swelling of lips; Tightness of her throat after receiving the 2nd dose; after receiving the 2nd dose, allergic reaction; This is a spontaneous report from a contactable nurse. The nurse reported for a female patient in response to the HCP letter sent in a cross-referenced case via telephonic. A female patient of an unspecified age received bnt162b2 (BNT162B2, solution for injection, lot number: EL9261; expiration date: May2021) dose 2 via an unspecified route of administration on 10Feb2021 as dose 2, single for COVID-19 immunisation. Medical history included asthma. The patient's concomitant medications was not reported. Historical vaccine included BNT162B2, lot number: EL9261; expiration date: May2021 dose 1 on 27Jan2021 as dose 1 single, for COVID-19 immunisation with injection site pain and slight redness. On an unspecified date in 2021 the patient experienced swelling of lips, tightness of her throat after receiving the 2nd dose, allergic reaction. She was feeling a little bit better now but has taken the week off of work to recover. The clinical outcome of the events was recovering.   Follow-up attempts are completed. No further information is expected.